Skip to main content

Table 6 Selected hepatic, hematologic and renal variables at pre-treatment and study exit (mean ± SD)

From: Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Variable (Laboratory reference range) Time Robenacoxib (n = 118) Placebo (n = 119) P value
   Mean (±SD) Casesa Mean (±SD) Casesa  
    High Low   High Low  
Serum
 Urea nitrogen, mg/dL (6–31 mg/dL) Pre-Treatment 18.1 (±7.3) 5 0 18.3 (±6.5) 5 0 0.078
Study Exit 14.9 (±4.8) 1 0 13.6 (±4.1) 0 0
 Creatinine, mg/dL (0.5–1.6 mg/dL) Pre-Treatment 0.91 (±0.25) 2 1 0.96 (±0.28) 2 2 0.763
Study Exit 0.79 (±0.21) 0 5 0.81 (±0.20) 0 1
 Alkaline phosphatase, U/L (5–131 U/L) Pre-Treatment 141.8 (±239.7) 26 0 112.0 (±214.7) 23 0 0.233
Study Exit 162.1 (±281.5) 30 0 116.4 (±176.3) 21 0
 Alanine aminotransferase, U/L (12–118 U/L) Pre-Treatment 55.3 (±41.6) 6 0 54.0 (±50.0) 7 1 0.613
Study Exit 53.7 (±49.4) 5 0 59.1 (±101.2) 5 1
 Aspartate aminotransferase, U/L (15–66 U/L) Pre-Treatment 29.6 (±10.5) 1 1 28.8 (±7.8) 0 1 0.449
Study Exit 37.5 (±46.6) 6 1 41.7 (±41.3) 11 0
 Total bilirubin, mg/dL (0.1–0.3 mg/dL) Pre-Treatment 0.14 (±0.06) 1 0 0.15 (±0.05) 0 0 0.431
Study Exit 0.15 (±0.07) 3 0 0.15 (±0.07) 2 0
 Total protein, g/dL (5.0–7.4 g/dL) Pre-Treatment 6.6 (±0.54) 7 0 6.5 (±0.57) 7 0 0.806
Study Exit 6.4 (±0.53) 4 0 6.4 (±0.57) 6 0
 Albumin, g/dL (2.7–4.4 g/dL) Pre-Treatment 3.6 (±0.34) 0 1 3.6 (±0.34) 0 1 0.501
Study Exit 3.5 (±0.32) 0 1 3.4 (±0.36) 0 2
Hematology
 Hemoglobin, g/dL (12.1–20.3 g/dL) Pre-Treatment 16.2 (±2.1) 2 3 16.4 (±1.8) 0 1 0.380
Study Exit 15.1 (±1.8) 0 8 15.0 (±1.8) 0 8
 Hematocrit, % (36–60%) Pre-Treatment 49.8 (±6.4) 5 1 50.2 (±5.5) 2 0 0.302
Study Exit 46.5 (±5.2) 0 5 46.2 (±4.9) 1 1
 Red blood cell count, 1012/L (4.8–9.3 1012/L) Pre-Treatment 6.8 (±0.89) 0 0 6.9 (±0.76) 0 0 0.406
Study Exit 6.3 (±0.78) 0 2 6.4 (±0.70) 0 0
 White blood cell count, 109/L (4.0–15.5 109/L) Pre-Treatment 10.9 (±3.7) 13 0 10.4 (±3.0) 6 1 0.454
Study Exit 13.5 (±4.0) 32 0 13.6 (±4.4) 37 0
Urine
 Urine specific gravity (1.015–1.050) Pre-Treatment 1.03 (±0.02) 23 8 1.03 (±0.01) 13 15 0.839
Study Exit 1.04 (±0.02) 27 5 1.04 (±0.02) 25 5
  1. P values were obtained from an analysis of covariance of the study exit values for each variable, with the pre-treatment value for each variable used as a covariate. Only cases for which both pre-treatment and study exit results were available were included in the analysis
  2. aNumber of cases with values higher and lower than the reference range pre-treatment and at study exit